Market Overview

UPDATE: Piper Jaffray Downgrades Geron Corporation to Neutral on Possible Safety Red Flags

Related GERN
9 Notable Biotechs Presenting At This Year's ASH Meeting
46 Biggest Movers From Yesterday
Your Daily Pharma Scoop: Geron's Fate, Celldex Commences Mid-Stage Study, Novartis's Tasigna (Seeking Alpha)

Piper Jaffray downgraded Geron Corporation (NASDAQ: GERN) from Overweight to Neutral and lowered the price target from $3.00 to $1.50.

Piper Jaffray analyst Charles C. Duncan wrote, "Geron reported 4Q/FY12 earnings yesterday that were largely in-line with our and consensus expectations. Importantly, the company ended the year with $96MM in cash and considering 2013 cash burn guidance of $33MM, we project this can fund operations into 2015. We expect R&D spending to increase in 2014 with the expanded clinical studies of imetelstat. Updates from the investigator-sponsored trial (IST) in myelofibrosis (MF) are expected near YE13. However, given an ongoing investigation into lab value abnormalities from the essential thrombocythemia (ET) study read out at ASH '12, and opaque visibility on imetelstat progress in MF, we are lowering our rating to Neutral and lowering our price target from $3 to $1.50 for Geron."

Geron Corporation closed at $1.29 on Wednesday.

Latest Ratings for GERN

Aug 2016BTIG ResearchInitiates Coverage onNeutral
Dec 2015Janney CapitalInitiates Coverage onBuy
Apr 2015OppenheimerInitiates Coverage onOutperform

View More Analyst Ratings for GERN
View the Latest Analyst Ratings

Posted-In: Piper JaffrayAnalyst Color Downgrades Analyst Ratings


Related Articles (GERN)

View Comments and Join the Discussion!

Partner Center